Phase contrast MRI is an early marker of micrometastatic breast cancer development in the rat brain

NMR in Biomedicine

Volumn 25, Issue 5, 2012, Pages 726-736

  Budde, Matthew D ^a   Gold, Eric ^a   Jordan, E Kay ^a   Smith Brown, Melissa ^a   Frank, Joseph A ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

Brain metastasis; Ferumoxides; MRI; Phase contrast; Vascular remodeling; Vessel co option

Indexed keywords

BRAIN METASTASIS; FERUMOXIDES; PHASE CONTRASTS; VASCULAR REMODELING; VESSEL CO-OPTION;

DISEASES; MAGNETIC RESONANCE IMAGING; MAGNETIC SUSCEPTIBILITY; PATHOLOGY; TUMORS;

NEUROIMAGING;

HEMOGLOBIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; BRAIN DAMAGE; BRAIN EDEMA; BRAIN METASTASIS; BRAIN TUMOR; BREAST CANCER; CARCINOGENESIS; CONTRAST ENHANCEMENT; ENDOTHELIUM CELL; HISTOPATHOLOGY; MAGNETISM; MICROMETASTASIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGENATION; PRIORITY JOURNAL; RAT; SENSITIVITY ANALYSIS; TUMOR CELL; TUMOR VOLUME;

ANIMALS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CONTRAST MEDIA; DEXTRANS; FEMALE; HEMOGLOBINS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; NEOPLASM MICROMETASTASIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, NUDE; TRANSPLANTATION, HETEROLOGOUS;

RATTUS;

EID: 84859644696     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1786     Document Type: Article

References (57)

1. Krumina G. Metastatic disease of the brain: parenchyma. Eur. Radiol. 2005; 15(3): 608-616.
2. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am. J. Pathol. 2005; 167(4): 913-920.
3. Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K, Hortobagyi GN, Rivera E. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 2007; 110(12): 2640-2647.
4. Cheng X, Hung MC. Breast cancer brain metastases. Cancer Metastasis Rev. 2007; 26(3-4): 635-643.
5. Gril B, Evans L, Palmieri D, Steeg PS. Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies. Eur. J. Cancer 2010; 46(7): 1204-1210.
6. Palmieri D, Chambers AF, Felding-Habermann B, Huang S, Steeg PS. The biology of metastasis to a sanctuary site. Clin. Cancer Res. 2007; 13(6): 1656-1662.
7. Kang Y. New tricks against an old foe: molecular dissection of metastasis tissue tropism in breast cancer. Breast Dis. 2006; 26: 129-138.
8. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat. Rev. Neurosci. 2007; 8(8): 610-622.
9. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 2003; 9(6): 677-684.
10. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359(6398): 843-845.
11. Kusters B, de Waal RM, Wesseling P, Verrijp K, Maass C, Heerschap A, Barentsz JO, Sweep F, Ruiter DJ, Leenders WP. Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma. Cancer Res. 2003; 63(17): 5408-5413.
12. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284(5422): 1994-1998.
13. Leenders WP, Küsters B, Verrijp K, Maass C, Wesseling P, Heerschap A, Ruiter D, Ryan A, de Waal R. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin. Cancer Res. 2004; 10(18 Pt 1): 6222-6230.
14. Claes A, Gambarota G, Hamans B, Van Tellingen O, Wesseling P, Maass C, Heerschap A, Leenders W. Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment. Int. J. Cancer 2008; 122(9): 1981-1986.
15. Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, Winkler F. Real-time imaging reveals the single steps of brain metastasis formation. Nat. Med. 2009; 16: 116-122.
16. Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ, Hill RP, Koch CJ, Krishna MC, Krohn KA, Lewis JS, Mason RP, Melillo G, Padhani AR, Powis G, Rajendran JG, Reba R, Robinson SP, Semenza GL, Swartz HM, Vaupel P, Yang D, Croft B, Hoffman J, Liu G, Stone H, Sullivan D. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int. J. Radiat. Biol. 2006; 82(10): 699-757.
17. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007; 26(2): 225-239.
18. Rodrigues L, Howe F, Griffiths J, Robinson S. Tumor R2* is a prognostic indicator of acute radiotherapeutic response in rodent tumors. J. Magn. Reson. Imaging 2004; 19(4): 482-488.
19. Mittal S, Wu Z, Neelavalli J, Haacke EM. Susceptibility-weighted imaging: technical aspects and clinical applications, part 2. Am. J. Neuroradiol. 2009; 30(2): 232-252.
20. Haacke EM, Mittal S, Wu Z, Neelavalli J, Cheng YC. Susceptibility-weighted imaging: technical aspects and clinical applications, part 1. Am. J. Neuroradiol. 2009; 30(1): 19-30.
21. Rauscher A, Sedlacik J, Barth M, Haacke EM, Reichenbach JR. Nonnvasive assessment of vascular architecture and function during modulated blood oxygenation using susceptibility weighted magnetic resonance imaging. Magn. Reson. Med. 2005; 54(1): 87-95.
22. Song HT, Jordan EK, Lewis BK, Gold E, Liu W, Frank JA. Quantitative T(2)* imaging of metastatic human breast cancer to brain in the nude rat at 3T. NMR Biomed. 2011; 24(3): 325-334.
23. Song HT, Jordan EK, Lewis BK, Liu W, Ganjei J, Klaunberg B, Despres D, Palmieri D, Frank JA. Rat model of metastatic breast cancer monitored by MRI at 3 tesla and bioluminescence imaging with histological correlation. J. Transl. Med. 2009; 7: 88.
24. Arbab AS, Yocum GT, Kalish H, Jordan EK, Anderson SA, Khakoo AY, Read EJ, Frank JA. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood 2004; 104(4): 1217-1223.
25. Himmelreich U, Weber R, Ramos-Cabrer P, Wegener S, Kandal K, Shapiro EM, Koretsky AP, Hoehn M. Improved stem cell MR detectability in animal models by modification of the inhalation gas. Mol. Imaging 2005; 4(2): 104-109.
26. Yang QX, Demeure RJ, Dardzinski BJ, Arnold BW, Smith MB. Multiple echo frequency-domain image contrast: improved signal-to-noise ratio and T2 (T2*) weighting. Magn. Reson. Med. 1999; 41(2): 423-428.
27. Helms G, Dechent P. Increased SNR and reduced distortions by averaging multiple gradient echo signals in 3D FLASH imaging of the human brain at 3T. J. Magn. Reson. Imaging 2009; 29(1): 198-204.
28. Noll DC, Nishimura DG, Macovski A. Homodyne detection in magnetic resonance imaging. IEEE Trans. Med. Imaging 1991; 10(2): 154-163.
29. Woods RP, Grafton ST, Watson JD, Sicotte NL, Mazziotta JC. Automated image registration: II. Intersubject validation of linear and nonlinear models. J. Comput. Assist. Tomogr. 1998; 22(1): 153-165.
30. Marques JP, Maddage R, Mlynarik V, Gruetter R. On the origin of the MR image phase contrast: an invivo MR microscopy study of the rat brain at 14.1T. Neuroimage 2009; 46(2): 345-352.
31. McAuley G, Schrag M, Sipos P, Sun SW, Obenaus A, Neelavalli J, Haacke EM, Holshouser B, Madacsi R, Kirsch W. Quantification of punctate iron sources using magnetic resonance phase. Magn. Reson. Med. 2010; 63(1): 106-115.
32. Lorger M, Felding-Habermann B. Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. Am. J. Pathol. 2010; 176(6): 2958-2971.
33. Heyn C, Ronald JA, Ramadan SS, Snir JA, Barry AM, MacKenzie LT, Mikulis DJ, Palmieri D, Bronder JL, Steeg PS, Yoneda T, MacDonald IC, Chambers AF, Rutt BK, Foster PJ. Invivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magn. Reson. Med. 2006; 56(5): 1001-1010.
34. Pawelczyk E, Arbab AS, Pandit S, Hu E, Frank JA. Expression of transferrin receptor and ferritin following ferumoxides-protamine sulfate labeling of cells: implications for cellular magnetic resonance imaging. NMR Biomed. 2006; 19(5): 581-592.
35. Arbab AS, Wilson LB, Ashari P, Jordan EK, Lewis BK, Frank JA. A model of lysosomal metabolism of dextran coated superparamagnetic iron oxide (SPIO) nanoparticles: implications for cellular magnetic resonance imaging. NMR Biomed. 2005; 18(6): 383-389.
36. Chambers AF, MacDonald IC, Schmidt EE, Morris VL, Groom AC. Clinical targets for anti-metastasis therapy. Adv. Cancer Res. 2000; 79: 91-121.
37. Dome B, Timar J, Paku S. A novel concept of glomeruloid body formation in experimental cerebral metastases. J. Neuropathol. Exp. Neurol. 2003; 62(6): 655-661.
38. Huang J, Soffer SZ, Kim ES, McCrudden KW, New T, Manley CA, Middlesworth W, O'Toole K, Yamashiro DJ, Kandel JJ. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol. Cancer Res. 2004; 2(1): 36-42.
39. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am. J. Pathol. 1995; 147(1): 9-19.
40. Vajkoczy P, Farhadi M, Gaumann A, Heidenreich R, Erber R, Wunder A, Tonn JC, Menger MD, Breier G. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J. Clin. Invest. 2002; 109(6): 777-785.
41. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999; 18(38): 5356-5362.
42. Broom KA, Anthony DC, Blamire AM, Waters S, Styles P, Perry VH, Sibson NR. MRI reveals that early changes in cerebral blood volume precede blood-brain barrier breakdown and overt pathology in MS-like lesions in rat brain. J. Cereb. Blood Flow Metab. 2005; 25(2): 204-216.
43. Carbonell WS, Ansorge O, Sibson N, Muschel R. The vascular basement membrane as "soil" in brain metastasis. PLoS One 2009; 4(6): e5857.
44. Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 1988; 240(4849): 177-184.
45. Fidler IJ, Balasubramanian K, Lin Q, Kim SW, Kim SJ. The brain microenvironment and cancer metastasis. Mol. Cells 2010; 30(2): 93-98.
46. Ribatti D, Vacca A, Dammacco F. New non-angiogenesis dependent pathways for tumour growth. Eur. J. Cancer 2003; 39(13): 1835-1841.
47. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009; 8: 20.
48. Fujiwara S, Nakagawa K, Harada H, Nagato S, Furukawa K, Teraoka M, Seno T, Oka K, Iwata S, Ohnishi T. Silencing hypoxia-inducible factor-1alpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas. Int. J. Oncol. 2007; 30(4): 793-802.
49. Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, Jain RK. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors invivo. Cancer Res. 2001; 61(16): 6020-6024.
50. Glunde K, Guggino SE, Solaiyappan M, Pathak AP, Ichikawa Y, Bhujwalla ZM. Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia 2003; 5(6): 533-545.
51. Sehgal V, Delproposto Z, Haddar D, Haacke EM, Sloan AE, Zamorano LJ, Barger G, Hu J, Xu Y, Prabhakaran KP, Elangovan IR, Neelavalli J, Reichenbach JR. Susceptibility-weighted imaging to visualize blood products and improve tumor contrast in the study of brain masses. J. Magn. Reson. Imaging 2006; 24(1): 41-51.
52. Dunn JF, O'Hara JA, Zaim-Wadghiri Y, Lei H, Meyerand ME, Grinberg OY, Hou H, Hoopes PJ, Demidenko E, Swartz HM. Changes in oxygenation of intracranial tumors with carbogen: a BOLD MRI and EPR oximetry study. J. Magn. Reson. Imaging 2002; 16(5): 511-521.
53. Baudelet C, Gallez B. How does blood oxygen level-dependent (BOLD) contrast correlate with oxygen partial pressure (pO2) inside tumors? Magn. Reson. Med. 2002; 48(6): 980-986.
54. Yablonskiy DA, Haacke EM. Theory of NMR signal behavior in magnetically inhomogeneous tissues: the static dephasing regime. Magn. Reson. Med. 1994; 32(6): 749-763.
55. Robinson SP, Collingridge DR, Howe FA, Rodrigues LM, Chaplin DJ, Griffiths JR. Tumour response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging. NMR Biomed. 1999; 12(2): 98-106.
56. Howe FA, Robinson SP, Rodrigues LM, Griffiths JR. Flow and oxygenation dependent (FLOOD) contrast MR imaging to monitor the response of rat tumors to carbogen breathing. Magn. Reson. Imaging 1999; 17(9): 1307-1318.
57. Burrell JS, Walker-Samuel S, Baker LC, Boult JK, Ryan AJ, Waterton JC, Halliday J, Robinson SP. Investigating temporal fluctuations in tumor vasculature with combined carbogen and ultrasmall superparamagnetic iron oxide particle (CUSPIO) imaging. Magn. Reson. Med. 2011; 66(1): 227-234.